New Enterprise Associates 15 L.P. 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 6:08 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | New Enterprise Associates 15 L.P. | 0 0.000% | -2,437,689 (Position Closed) | Filing |
| 2022-02-07 1:58 pm Unchanged | 2021-12-31 | 13G | Inozyme Pharma, Inc. INZY | New Enterprise Associates 15 L.P. | 2,437,689 10.300% | 0 (Unchanged) | Filing |
| 2021-02-12 1:30 pm Purchase | 2020-12-31 | 13G | Inozyme Pharma, Inc. INZY | New Enterprise Associates 15 L.P. | 2,437,689 10.400% | 2,437,689 (New Position) | Filing |